PACIRA BIOSCIENCES INC (PCRX) Stock News

USA - Nasdaq - NASDAQ:PCRX - US6951271005 - Common Stock

23.05 USD

+0.25 (+1.1%)

Last: 11/21/2025, 8:00:01 PM

23.05 USD

0 (0%)

After Hours: 11/21/2025, 8:00:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

PCRX Latest News, Press Relases and Analysis

All

Press Releases

11 days ago - By: Pacira BioSciences

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

11 days ago - By: Pacira BioSciences

Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences

16 days ago - By: Zacks Investment Research

Pacira (PCRX) Reports Q3 Earnings: What Key Metrics Have to Say

16 days ago - By: Zacks Investment Research - Mentions: ATRA

Pacira (PCRX) Tops Q3 Earnings Estimates

16 days ago - By: Pacira BioSciences

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

16 days ago - By: Benzinga - Mentions: STVN PODD AMRK SOLV ...

Earnings Scheduled For November 6, 2025

4 months ago - By: The Motley Fool

Pacira (PCRX) Q2 Revenue Rises 1.7%

4 months ago - By: Pacira BioSciences

Pacira BioSciences Reports Second Quarter 2025 Financial Results

16 days ago - By: Pacira BioSciences

Pacira BioSciences Reports Third Quarter 2025 Financial Results; Increases Full-year Gross Margin Guidance

17 days ago - By: Pacira BioSciences

Pacira BioSciences Concludes Patient Enrollment in Part A of Phase 2 Study Evaluating Safety and Efficacy of PCRX-201 for the Treatment of Osteoarthritis of the Knee

18 days ago - By: Pacira BioSciences

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

18 days ago - By: Pacira BioSciences

Pacira BioSciences Enters Exclusive License Agreement with AmacaThera for its Novel Long-acting Analgesic for Postsurgical Pain Control

4 months ago - By: Benzinga - Mentions: AFG CXDO YUM PACK ...

Earnings Scheduled For August 5, 2025

23 days ago - By: Zacks Investment Research - Mentions: MRNA

Earnings Preview: Moderna (MRNA) Q3 Earnings Expected to Decline

23 days ago - By: Pacira BioSciences

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

23 days ago - By: Pacira BioSciences

Pacira to Report Third Quarter 2025 Financial Results on Thursday November 6, 2025

24 days ago - By: Zacks Investment Research - Mentions: ANAB

Pacira (PCRX) Expected to Beat Earnings Estimates: Should You Buy?

25 days ago - By: Pacira BioSciences

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

25 days ago - By: Pacira BioSciences

Pacira BioSciences Presents Updated Three-Year Data Demonstrating Sustained Efficacy and Safety of PCRX-201 Gene Therapy for Patients with Moderate-to-Severe Osteoarthritis of the Knee

a month ago - By: Pacira BioSciences

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

a month ago - By: Pacira BioSciences

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from Qilu Pharmaceutical (Hainan) Co., Ltd. for EXPAREL®

a month ago - By: Pacira BioSciences

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

a month ago - By: Pacira BioSciences

Pacira BioSciences to Present New Data from Three Real-World Studies with EXPAREL®

a month ago - By: Pacira BioSciences

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

a month ago - By: Pacira BioSciences

Pacira BioSciences Notified of Abbreviated New Drug Application Filing from The WhiteOak Group for EXPAREL®

a month ago - By: Pacira BioSciences

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

a month ago - By: Pacira BioSciences

Pacira BioSciences to Present 3-Year Data Demonstrating Sustained Pain and Function Improvements in Knee Osteoarthritis with Investigational PCRX-201 Gene Therapy

2 months ago - By: Pacira BioSciences

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Pacira BioSciences

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Pacira BioSciences

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Pacira BioSciences

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Zacks Investment Research

Here's What Key Metrics Tell Us About Pacira (PCRX) Q2 Earnings

4 months ago - By: Zacks Investment Research - Mentions: RCUS

Pacira (PCRX) Tops Q2 Earnings Estimates

4 months ago - By: Pacira BioSciences

Pacira BioSciences Reports Second Quarter 2025 Financial Results